Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Exploring the Safety, Tolerability, and Antiviral Effect of Substituting 600 mg Racivir [PSI-5004] for 3TC [lamivudine] in HIV-Infected Subjects Who Have the M184V Mutation and Are Currently Failing on a HAART [highly active antiretroviral therapy Regimen Containing Lamivudine
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs PSI 5004 (Primary) ; Lamivudine
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 09 Jan 2008 New trial record.